Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

scroll

scroll-down

Lead Program

pipeline-pic

Lead Program

 

Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.

 

Lead Program >>